CJC-1295 DAC + Ipamorelin + GHRP-2 Triple Blend

Description

Disclaimer: This compound is provided strictly for laboratory and scientific research purposes only. It is not approved by the U.S. Food and Drug Administration (FDA) for human or veterinary use, including ingestion, injection, or any form of administration.

WADA Notice: All three components (CJC-1295 DAC, Ipamorelin, GHRP-2) are prohibited under WADA S2.2.4 – Growth Hormone-Releasing Peptides – in- and out-of-competition on the 2026 WADA Prohibited List.

Chemical Properties of the Compound

Overview

CJC-1295 DAC + Ipamorelin + GHRP-2 Triple Blend co-formulates three mechanistically distinct GH secretagogue peptides at 2mg each. CJC-1295 DAC activates GHRHR via Gs/cAMP with ~6–8-day extended half-life via DAC-albumin conjugation (Jetté et al. 2005, PMID 15817669). Ipamorelin activates GHS-R1a via Gq/Ca²⁺ with high selectivity (no ACTH/cortisol, Raun et al. 1998, PMID 9849822). GHRP-2 activates GHS-R1a with ACTH/cortisol co-stimulation. Three receptor targets, two signalling cascades, one formulation. All WADA S2.2.4. Not FDA-approved. Laboratory research only.

Working Mechanism of Triple Blend

CJC-1295 DAC → GHRHR/Gs/cAMP (Extended): DAC lysine modification enables covalent albumin binding post-reconstitution, extending half-life to ~6–8 days. GHRHR activation → Gs → cAMP → PKA → pulsatile GH exocytosis with sustained basal GH elevation (Jetté et al. 2005, PMID 15817669).

Ipamorelin → GHS-R1a/Gq/Ca²⁺ (Selective): GHS-R1a activation via Gq/IP3/Ca²⁺ → GH exocytosis. No ACTH/cortisol co-stimulation at 200× ED50. Provides GHS-R1a component without adrenal confound (Raun et al. 1998).

GHRP-2 → GHS-R1a/Gq/Ca²⁺ (Non-Selective): Same Gq/Ca²⁺ cascade as ipamorelin but with ACTH/cortisol co-stimulation (Muccioli et al. 2007). Provides a mechanistic contrast to ipamorelin in the same GH axis experimental system.

Research Findings / Research Applications

•       Triple-pathway GH axis pharmacology: GHRHR + GHS-R1a dual input in primary pituitary somatotroph and co-transfected cell models
•       Ipamorelin vs GHRP-2 comparative selectivity within fixed-ratio blend: ACTH/cortisol co-stimulation quantification
•       CJC-1295 DAC DAC-albumin pharmacokinetics: GHRHR occupancy modelling and sustained vs pulsatile GH secretory profile
•       Synergistic Gs/cAMP + Gq/Ca²⁺ pathway convergence research in pituitary somatotroph models

Note: These findings are based on early-stage and preclinical research. Results are not consistent across all models, and data remain limited without validation in human clinical settings.

Risks & Handling Information

•       PPE: gloves, lab coat, eye protection. All three are CNS-active GH secretagogues. Institutional biosafety review is strongly recommended. Reconstitute aseptically.
•       Risk Tier: CRITICAL/HIGHEST – Three WADA-prohibited GH secretagogues. GHRP-2 ACTH/cortisol co-stimulation. CJC-1295 DAC extended half-life (~6–8 days). No human safety data for triple-blend. No long-term toxicity data. GH axis abuse potential is plausible but uncharacterised.
•       −20°C sealed, light-protected. Do not re-freeze. Stable ≥24 months lyophilized.

FAQs

Why include both ipamorelin and GHRP-2?

Both activate GHS-R1a but with different selectivity profiles. Including both at a 1:1 ratio allows direct comparative research into selective vs non-selective GHS-R1a agonism within the same GH axis experimental system.

WADA classification?

All three: WADA S2.2.4 – Growth Hormone-Releasing Peptides. Prohibited in- and out-of-competition on the 2026 WADA Prohibited List.

References

•       Jetté L, Léger R, Thibaudeau K, et al. Human GRF1−29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295. Endocrinology. 2005;146(7):3052–3058. https://pubmed.ncbi.nlm.nih.gov/15817669/
•       Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998;139(5):552–561. https://pubmed.ncbi.nlm.nih.gov/9849822/

This content is presented exclusively for educational purposes and should not be construed as medical advice. THE MATERIALS REFERENCED HEREIN ARE EXCLUSIVELY INTENDED FOR LABORATORY AND RESEARCH USE.

Any clinical research initiatives must be conducted under the guidance of the relevant Institutional Review Board (IRB). Similarly, preclinical research involving animals must comply with the directives of the Institutional Animal Care and Use Committee (IACUC), adhering to the standards delineated by the Animal Welfare Act (AWA).

Upon finalizing your order and payment, you explicitly acknowledge and agree to adhere to our Terms and Conditions. Contact us at 419-707-5450 or support@bc9.co. 

IMPORTANT NOTICE: All products showcased on our platform are EXCLUSIVELY INTENDED FOR LABORATORY AND RESEARCH APPLICATIONS. They are expressly not intended for veterinary or human utilization.